Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell Therapy | MicrobiomeTrials← Back to trialsNCT05725720
Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell Therapy
RecruitingOBSERVATIONAL
Trial Details
Start: 2023-03-23Est. Completion: 2027-07
Enrollment target: 69 participants Locations- Institute Of Hematology "Seràgnoli", Bologna, Italy
Other microbiome trials you might be interested in
B-cell Acute Lymphoblastic LeukemiaDiffuse Large B-cell LymphomaBurkitt LymphomaNeuroblastomaEwing Sarcoma
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab…
Los Angeles, United StatesEst. completion Mar 31, 2029
Lymphoma, Non-HodgkinLymphoma, FollicularLymphoma, Large B-Cell, Diffuse
Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and …
Denver, United StatesEst. completion Jul 1, 2030
Diffuse Large B-cell Lymphoma (DLBCL)CardiotoxicityLymphoma
This trial is to evaluate if dexrazoxane is safer and more effective than liposomal doxorubicin in preventing heart fail…
Boston, United StatesEst. completion Dec 31, 2030